World Wires · story 5235 · unverified · 1 source(s)

Immix Biopharma reports 89% complete response rate in NEXICART-2

Immix Biopharma announced an 89% complete response rate and high MRD-negativity at an interim update for its NEXICART-2 trial treating AL amyloidosis.

Open in the desk

Coverage

• Immix Biopharma reports 89% complete response rate in NEXICART-2 GlobeNewswire: public companies · tier D · clear net · 2026-09-29 11:00 UTC

What this site indexes